Carl Ola Landgren

List of Publications by Year
in descending order

288 papers	16,578 citations	34016 52 h-index	17546 121 g-index
300 all docs	300 docs citations	300 times ranked	13007 citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
3	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 2009, 113, 5412-5417.	0.6	904
4	Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood, 2009, 113, 4992-5001.	0.6	362
5	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica, 2015, 100, 107-113.	1.7	356
6	B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2009, 360, 659-667.	13.9	322
7	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood, 2010, 116, 5501-5506.	0.6	308
8	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2020, 396, 186-197.	6.3	299
9	Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood, 2006, 107, 904-906.	0.6	280
10	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. Journal of Clinical Oncology, 2007, 25, 1993-1999.	0.8	275
11	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2015, 1, 746.	3.4	266
12	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24â€‰577 first-degree relatives of 11â€‰039 patients with myeloproliferative neoplasms in Sweden. Blood, 2008, 112, 2199-2204.	0.6	226
13	Smoldering multiple myeloma. Blood, 2015, 125, 3069-3075.	0.6	211
14	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, 2019, 291, 5-13.	3.6	209
15	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood, 2010, 115, 4991-4998.	0.6	204
16	Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Caseâ€“Control Study in Scandinavia. Journal of the National Cancer Institute, 2006, 98, 1321-1330.	3.0	179
17	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nature Medicine, 2018, 24, 1867-1876.	15.2	179
18	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood, 2011, 118, 4086-4092.	0.6	173

#	Article	IF	Citations
19	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clinic Proceedings, 2007, 82, 1468-1473.	1.4	142
20	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood, 2009, 113, 6386-6391.	0.6	137
21	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood, 2010, 116, 1056-1059.	0.6	137
22	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood, 2009, 114, 791-795.	0.6	133
23	Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. International Journal of Cancer, 2006, 118, 3095-3098.	2.3	125
24	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	1.7	112
25	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica, 2012, 97, 854-858.	1.7	110
26	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European Journal of Haematology, 2018, 101, 237-244.	1.1	107
27	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood, 2014, 123, 338-345.	0.6	105
28	Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology, 2010, 28, 773-779.	0.8	101
29	Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012. American Journal of Gastroenterology, 2015, 110, 455-461.	0.2	99
30	Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917.	5.8	99
31	New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 5428-5433.	3.2	98
32	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature Reviews Clinical Oncology, 2015, 12, 286-295.	12.5	97
33	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica, 2009, 94, 1714-1720.	1.7	95
34	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA Oncology, 2015, 1, 168.	3.4	93
35	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. Blood, 2017, 130, 742-742.	0.6	92
36	Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging â€œearly myelomaâ€• Leukemia and Lymphoma, 2013, 54, 1355-1363.	0.6	90

#	Article	IF	Citations
37	Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood, 2007, 109, 2198-2201.	0.6	89
38	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica, 2018, 103, e412-e415.	1.7	87
39	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leukemia and Lymphoma, 2013, 54, 2215-2218.	0.6	86
40	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances, 2017, 1, 728-732.	2.5	84
41	Revealing the Impact of Structural Variants in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 258-273.	2.6	81
42	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 65-76.	5.1	80
43	Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leukemia Research, 2014, 38, 371-376.	0.4	76
44	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e30-e37.	0.2	75
45	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology, 2020, 295, 606-615.	3.6	73
46	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research, 2017, 23, 3980-3993.	3.2	71
47	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. Blood, 2018, 132, 959-959.	0.6	71
48	Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. Journal of Molecular Diagnostics, 2019, 21, 330-342.	1.2	69
49	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	5.8	68
50	Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood, 2006, 108, 292-296.	0.6	63
51	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	3.4	63
52	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research, 2019, 7, 1047-1053.	1.6	59
53	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Investigational New Drugs, 2020, 38, 1448-1453.	1.2	58
54	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia and Lymphoma, 2017, 58, 1823-1831.	0.6	57

#	Article	IF	Citations
55	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncology, 2019, 5, 1293.	3.4	57
56	Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. JAMA Oncology, 2015, 1, 1061.	3.4	56
57	Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2342-2347.	1.1	55
58	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia, 2020, 34, 1840-1852.	3.3	55
59	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54
60	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Seminars in Oncology, 2016, 43, 682-689.	0.8	53
61	Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 791-798.	1.2	52
62	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer Journal, 2021, 11, 94.	2.8	52
63	Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy, 2015, 35, 1173-1188.	1.2	51
64	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leukemia and Lymphoma, 2018, 59, 2056-2067.	0.6	50
65	Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Advances, 2019, 3, 2040-2044.	2.5	50
66	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	2.2	50
67	Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical Biochemistry, 2018, 51, 66-71.	0.8	49
68	Multiple Myeloma Precursor Disease. JAMA - Journal of the American Medical Association, 2010, 304, 2397.	3.8	48
69	Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia, 2021, 35, 255-258.	3.3	48
70	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Advances, 2017, 1, 2186-2192.	2.5	47
71	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	2.6	46
72	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. Haematologica, 2015, 100, 1340-1349.	1.7	43

#	Article	IF	Citations
73	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	0.6	41
74	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. JAMA Oncology, 2020, 6, 425.	3.4	41
75	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	5.8	41
76	New Aspects in Descriptive, Etiologic, and Molecular Epidemiology of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2007, 21, 825-840.	0.9	40
77	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal, 2019, 9, 101.	2.8	40
78	Comparison of MALDIâ€TOF mass spectrometry analysis of peripheral blood and bone marrowâ€based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. British Journal of Haematology, 2020, 189, 904-907.	1.2	40
79	Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. International Journal of Cancer, 2006, 120, 1099-1102.	2.3	39
80	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treatment and Research, 2016, 169, 3-12.	0.2	39
81	Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma. Leukemia, 2020, 34, 1476-1480.	3.3	39
82	Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. Archives of Internal Medicine, 2007, 167, 1189.	4.3	38
83	Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. JAMA Oncology, 2018, 4, 821.	3.4	38
84	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Advances, 2017, 1, 1911-1918.	2.5	37
85	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics, 2015, 17, 669-678.	1.2	36
86	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia, 2019, 33, 2127-2143.	3.3	36
87	B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer Journal, 2020, 10, 73.	2.8	36
88	Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry Part B - Clinical Cytometry, 2016, 90, 14-20.	0.7	35
89	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of Blood and Marrow Transplantation, 2018, 24, 871-876.	2.0	35
90	Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica, 2006, 91, 1697-700.	1.7	35

#	Article	IF	Citations
91	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 862-862.	0.6	34
92	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. JAMA Oncology, 2018, 4, 1781.	3.4	33
93	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 87-97.	0.9	32
94	The mutagenic impact of melphalan in multiple myeloma. Leukemia, 2021, 35, 2145-2150.	3.3	32
95	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood, 2022, 140, 491-503.	0.6	32
96	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Seminars in Hematology, 2018, 55, 44-50.	1.8	31
97	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	2.8	30
98	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. Clinical Cancer Research, 2014, 20, 804-813.	3.2	29
99	Biological determinants of health disparities in multiple myeloma. Blood Cancer Journal, 2018, 8, 85.	2.8	29
100	Fractures and survival in multiple myeloma: results from a population-based study. Haematologica, 2020, 105, 1067-1073.	1.7	29
101	Second malignancies in multiple myeloma; emerging patterns and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101144.	0.7	27
102	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications, 2021, 12, 5172.	5.8	27
103	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	3.2	26
104	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology American Society of Hematology Education Program, 2010, 2010, 295-302.	0.9	25
105	Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia and Lymphoma, 2010, 51, 2159-2170.	0.6	25
106	Shall we treat smoldering multiple myeloma in the near future?. Hematology American Society of Hematology Education Program, 2017, 2017, 194-204.	0.9	25
107	MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. Seminars in Hematology, 2018, 55, 1-3.	1.8	25
108	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS ONE, 2019, 14, e0211600.	1.1	24

#	Article	IF	Citations
109	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284.	2.6	24
110	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. Leukemia and Lymphoma, 2015, 56, 1416-1424.	0.6	23
111	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia and Lymphoma, 2016, 57, 1114-1121.	0.6	23
112	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. Blood Advances, 2017, 1, 2790-2798.	2.5	23
113	Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. journal of applied laboratory medicine, The, 2019, 3, 857-863.	0.6	23
114	The role of highâ€dose melphalan with autologous stemâ€cell transplant in multiple myeloma: is it time for a paradigm shift?. British Journal of Haematology, 2020, 191, 692-703.	1.2	23
115	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood, 2019, 134, 3116-3116.	0.6	23
116	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology, 2019, 94, 1364-1373.	2.0	22
117	Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma. American Journal of Surgical Pathology, 2020, 44, 838-848.	2.1	22
118	Mass Spectrometryâ€"Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. Journal of Molecular Diagnostics, 2020, 22, 901-911.	1.2	22
119	Chromothripsis as a pathogenic driver of multiple myeloma. Seminars in Cell and Developmental Biology, 2022, 123, 115-123.	2.3	22
120	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 258-267.	2.0	21
121	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncology, 2021, 7, 132.	3.4	21
122	mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Communications Biology, 2021, 4, 424.	2.0	21
123	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Annals of Hematology, 2017, 96, 261-269.	0.8	20
124	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clinical Cancer Research, 2021, 27, 15-23.	3.2	20
125	Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE, 2018, 13, e0206047.	1.1	19
126	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. Advances in Cell and Gene Therapy, 2019, 2, e26.	0.6	19

#	Article	IF	Citations
127	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	1.2	19
128	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	15.2	19
129	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	2.0	18
130	Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Reviews, 2021, 46, 100732.	2.8	18
131	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. Obesity, 2017, 25, 1317-1320.	1.5	17
132	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 198-200.	0.2	17
133	Pesticide use and kidney function among farmers in the Biomarkers of Exposure and Effect in Agriculture study. Environmental Research, 2021, 199, 111276.	3.7	17
134	Role of MicroRNAs From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Seminars in Hematology, 2011, 48, 39-45.	1.8	16
135	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	0.6	16
136	Host-related immunodeficiency in the development of multiple myeloma. Leukemia and Lymphoma, 2018, 59, 1127-1132.	0.6	16
137	Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of Blood and Marrow Transplantation, 2019, 25, 41-46.	2.0	15
138	Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. Environmental Health Perspectives, 2021, 129, 17003.	2.8	15
139	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. Thrombosis Research, 2020, 186, 86-92.	0.8	14
140	Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. Annals of Hematology, 2016, 95, 871-879.	0.8	13
141	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	0.6	13
142	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. Blood, 2020, 136, 26-27.	0.6	13
143	Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. Bone Marrow Transplantation, 2018, 53, 1445-1449.	1.3	12
144	Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leukemia and Lymphoma, 2018, 59, 221-224.	0.6	12

#	Article	IF	Citations
145	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
146	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology, 2021, 53, 385-399.	0.3	12
147	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	3.4	12
148	Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. European Journal of Clinical & Medical Oncology, 2010, 2, 119-126.	0.0	12
149	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e493-e503.	1.8	11
150	Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. Leukemia and Lymphoma, 2017, 58, 1123-1129.	0.6	11
151	Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Hematology American Society of Hematology Education Program, 2021, 2021, 662-672.	0.9	11
152	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. American Journal of Hematology, 2019, 94, 794-802.	2.0	10
153	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2020, 26, 204-208.	2.0	10
154	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. JNCI Cancer Spectrum, 2020, 4, pkz104.	1.4	10
155	Positive selection as the unifying force for clonal evolution in multiple myeloma. Leukemia, 2021, 35, 1511-1515.	3.3	10
156	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m²) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	2.0	10
157	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	0.6	10
158	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. Blood, 2020, 136, 43-45.	0.6	10
159	Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leukemia and Lymphoma, 2012, 53, 721-724.	0.6	9
160	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	2.8	9
161	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e213-e220.	0.2	9
162	Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future. Best Practice and Research in Clinical Haematology, 2020, 33, 101140.	0.7	9

#	Article	IF	Citations
163	Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. Blood Cancer Journal, 2020, 10, 76.	2.8	9
164	Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Practice and Research in Clinical Haematology, 2020, 33, 101148.	0.7	9
165	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value in Health, 2020, 23, 441-450.	0.1	9
166	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6479-6490.	3.2	9
167	Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies. Blood, 2019, 134, 1891-1891.	0.6	9
168	Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunities. Oncology, 2011, 25, 589-90.	0.4	9
169	Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. Seminars in Hematology, 2011, 48, 1-3.	1.8	8
170	Survival in patients with familial and sporadic myeloproliferative neoplasms. Blood, 2015, 125, 3665-3666.	0.6	8
171	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 58-65.	2.0	8
172	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European Journal of Haematology, 2021, 107, 275-282.	1.1	8
173	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia, 2021, , .	3.3	8
174	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
175	Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. Blood, 2015, 126, 4257-4257.	0.6	8
176	Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma. Blood, 2020, 136, 28-28.	0.6	8
177	Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology, 2011, 48, 66-72.	1.8	7
178	Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia and Lymphoma, 2017, 58, 1757-1759.	0.6	7
179	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clinica Chimica Acta, 2021, 516, 136-141.	0.5	7
180	Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study. Blood, 2018, 132, 799-799.	0.6	7

#	Article	IF	Citations
181	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. Blood, 2019, 134, 1835-1835.	0.6	7
182	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	0.6	7
183	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. Blood Cancer Journal, 2021, 11, 191.	2.8	7
184	Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer Journal, 2022, 12, 70.	2.8	7
185	Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer Journal, 2022, 12, .	2.8	7
186	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncology, The, 2020, 21, e540.	5.1	6
187	Isotype-Specific Heavy/Light Chain (HLC) Suppression as a Predictor of Myeloma Development in Monoclonal Gammopathy of Undetermined Significance (MGUS).. Blood, 2009, 114, 1788-1788.	0.6	6
188	Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center. Blood, 2015, 126, 4265-4265.	0.6	6
189	Monoclonal gammopathy of undetermined significance and WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 187-193.	0.7	5
190	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	3.2	5
191	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or NaÃ¯ve to Daratumumab (dara). Blood, 2019, 134, 1867-1867.	0.6	5
192	Revealing the Impact of Recurrent and Rare Structural Variations in Multiple Myeloma. Blood, 2019, 134, 576-576.	0.6	5
193	Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents. Blood, 2015, 126, 1996-1996.	0.6	5
194	Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <scp>CANDOR</scp> study. British Journal of Haematology, 2022, 198, 988-993.	1.2	5
195	Modern Myeloma Therapy + Sustained Minimal Residual Diseaseâ€“Negative = (Functional) Cure!. Journal of Clinical Oncology, 2022, 40, 2863-2866.	0.8	5
196	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia and Lymphoma, 2017, 58, 2962-2965.	0.6	4
197	Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2020, 83, 269-278.	1.1	4
198	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 2022, 107, 284-286.	1.7	4

#	Article	IF	Citations
199	Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study. Blood, 2018, 132, 3281-3281.	0.6	4
200	Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 4619-4619.	0.6	4
201	African-American Multiple Myeloma Patients Have a Better Survival Than Caucasian Patients: a Population-Based Study Including 28,636 Patients.. Blood, 2009, 114, 1832-1832.	0.6	4
202	Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients. Blood, 2012, 120, 1805-1805.	0.6	4
203	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 1785-1785.	0.6	4
204	Timing the Initiation of Multiple Myeloma. SSRN Electronic Journal, 0, , .	0.4	4
205	Myeloma imaging: time to move on!. Leukemia and Lymphoma, 2016, 57, 1499-1500.	0.6	3
206	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemotherapy and Pharmacology, 2017, 80, 217-221.	1.1	3
207	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports, 2019, 9, 14884.	1.6	3
208	Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. Blood, 2018, 132, 3184-3184.	0.6	3
209	Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. Blood, 2020, 136, 32-34.	0.6	3
210	Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005.. Blood, 2009, 114, 1553-1553.	0.6	3
211	The Road to Treating Smoldering Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S59-S64.	0.2	2
212	Racial/ethnic disparities: need more work!. Blood, 2017, 130, 1685-1686.	0.6	2
213	Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. Leukemia and Lymphoma, 2018, 59, 178-186.	0.6	2
214	Management of multiple myeloma during COVID-19 pandemic. Leukemia Research Reports, 2020, 14, 100212.	0.2	2
215	A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up. Blood, 2018, 132, 1957-1957.	0.6	2
216	MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone. Blood, 2018, 132, 1983-1983.	0.6	2

#	Article	IF	Citations
217	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 3127-3127.	0.6	2
218	MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy. Blood, 2019, 134, 4377-4377.	0.6	2
219	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease. Blood, 2020, 136, 47-48.	0.6	2
220	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. Blood, 2009, 114, 1872-1872.	0.6	2
221	Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma. Blood, 2020, 136, 8-9.	0.6	2
222	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 52-53.	0.6	2
223	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	0.6	2
224	Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Blood Cancer Journal, 2022, 12, 51.	2.8	2
225	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	3.2	2
226	Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. Seminars in Oncology, 2016, 43, 703-706.	0.8	1
227	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
228	Multiple myeloma: Current advances and future directions. Best Practice and Research in Clinical Haematology, 2020, 33, 101155.	0.7	1
229	Identifying Ultra-High Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 3192-3192.	0.6	1
230	Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy. Blood, 2018, 132, 4751-4751.	0.6	1
231	Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. Blood, 2014, 124, 848-848.	0.6	1
232	The Majority of Patients with Relapsing Light Chain (AL) Amyloidosis Are Not Eligible for Enrollment Onto Clinical Trials: Using Screen Failures to Define Major Unmet Medical Needs. Blood, 2015, 126, 1786-1786.	0.6	1
233	Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study. Blood, 2015, 126, 3178-3178.	0.6	1
234	Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.. Journal of Clinical Oncology, 2019, 37, e19525-e19525.	0.8	1

#	Article	IF	Citations
235	Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Subsequent Multiple Myeloma among African-American and White Veterans in the U.S.. Blood, 2005, 106, 1541-1541.	0.6	1
236	Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity. Blood, 2012, 120, 4966-4966.	0.6	1
237	Success of Online Curriculum-Based Education in the Management of Multiple Myeloma and Continuing Gaps Among Hematologists/Oncologists. Blood, 2015, 126, 3320-3320.	0.6	1
238	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. Blood, 2018, 132, 3169-3169.	0.6	1
239	Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma. Blood, 2018, 132, 3167-3167.	0.6	1
240	Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. Blood, 2019, 134, 5444-5444.	0.6	1
241	High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster. Blood, 2019, 134, 3720-3720.	0.6	1
242	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood, 2021, 138, 4759-4759.	0.6	1
243	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 3271-3271.	0.6	1
244	Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14). Blood, 2021, 138, 2270-2270.	0.6	1
245	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. Blood, 2020, 136, 37-38.	0.6	1
246	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 7-7.	0.6	1
247	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. Blood, 2020, 136, 10-10.	0.6	1
248	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. Seminars in Oncology, 2022, , .	0.8	1
249	Diagnosed with myeloma before age 40. Blood, 2021, 138, 2601-2602.	0.6	1
250	Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leukemia and Lymphoma, 2022, 63, 2413-2421.	0.6	1
251	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10.	0.6	1
252	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. Leukemia and Lymphoma, 2022, 63, 2760-2761.	0.6	1

#	Article	IF	Citations
253	Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma. Current Radiology Reports, 2016, 4, 1.	0.4	0
254	Serum protein markers of clonal heterogeneity in myeloma. Lancet Haematology,the, 2017, 4, e565-e566.	2.2	0
255	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a populationâ€based study. British Journal of Haematology, 2019, 186, 37-44.	1.2	0
256	Future prospects of chimeric antigen receptor Tâ€cell therapy for multiple myeloma. Advances in Cell and Gene Therapy, 2020, 3, e72.	0.6	0
257	Familial patterns of hematologic precursors. Blood, 2021, 137, 1992-1993.	0.6	0
258	Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study.. Blood, 2009, 114, 1378-1378.	0.6	0
259	Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients.. Blood, 2009, 114, 2838-2838.	0.6	0
260	Obesity is Associated with a 2-Fold Elevated Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) Among African-American and Caucasian Women.. Blood, 2009, 114, 4876-4876.	0.6	0
261	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. Blood, 2012, 120, 570-570.	0.6	0
262	Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma. Blood, 2014, 124, 3856-3856.	0.6	0
263	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. Blood, 2015, 126, 1975-1975.	0.6	0
264	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. Blood, 2016, 128, 2090-2090.	0.6	0
265	Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases. Blood, 2018, 132, 1914-1914.	0.6	0
266	Measurement of Serum microRNAs in US Veterans with Monoclonal Gammopathy of Undetermined Significance. Blood, 2018, 132, 5576-5576.	0.6	0
267	Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood, 2018, 132, 5591-5591.	0.6	0
268	Risk Factors for Acute Myeloid Leukemia and Myelodysplastic Syndromes in Patients with Multiple Myeloma: An Updated Analysis. Blood, 2018, 132, 4437-4437.	0.6	0
269	Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection. Blood, 2018, 132, 4475-4475.	0.6	0
270	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood, 2018, 132, 5588-5588.	0.6	0

#	Article	IF	Citations
271	The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study. Blood, 2018, 132, 4490-4490.	0.6	0
272	Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma. Blood, 2019, 134, 3060-3060.	0.6	0
273	FDA Analysis: Impact of Body Mass Index (BMI) on Outcomes in Relapsed-Refractory Multiple Myeloma. Blood, 2019, 134, 5505-5505.	0.6	0
274	Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree. Blood, 2019, 134, 1794-1794.	0.6	0
275	Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma. Blood, 2019, 134, 4367-4367.	0.6	0
276	Timing the Initiation of Multiple Myeloma. Blood, 2019, 134, 573-573.	0.6	0
277	Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence. Blood, 2019, 134, 3380-3380.	0.6	0
278	An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. Blood, 2019, 134, 5554-5554.	0.6	0
279	The Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	0.6	0
280	Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities. Blood, 2021, 138, 4958-4958.	0.6	0
281	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). Blood, 2021, 138, 154-154.	0.6	0
282	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	0.6	0
283	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	0.6	0
284	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	0.6	0
285	The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd). Blood, 2020, 136, 11-12.	0.6	0
286	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	0.6	0
287	Duration of Post-Autologous Hematopoietic Cell Transplant Anemia and Thrombocytopenia Are Associated with Prolonged Hospital Length-of-Stay for Multiple Myeloma Patients. Blood, 2020, 136, 5-6.	0.6	0
288	Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Touch Reviews in Oncology & Haematology, 2021, 17, 101.	0.1	0